{"id":"W3134768182","doi":"10.1200/jco.2021.39.6_suppl.6","title":"177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Cabazitaxel; Medicine; Docetaxel; Prostate cancer; Clinical endpoint; Hazard ratio; Internal medicine; Adverse effect; Progression-free survival; Oncology; Urology; Confidence interval; Randomized controlled trial; Cancer; Overall survival; Androgen deprivation therapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160435,0.0004151191,0.0008567382,0.0003562334,0.0001873587,0.0003511089,0.0003907221,0.0005083331,0.002903323],"category_scores_gemma":[0.0005329959,0.0002090738,0.0006791141,0.0002527722,0.0003234982,0.0003377933,0.0001908483,0.0009831041,0.0004079377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004887864,"about_ca_system_score_gemma":0.0005752046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001060491,"about_ca_topic_score_gemma":0.003590288,"domain_scores_codex":[0.9998378,0.00008507332,0.00001040007,0.00002372853,0.00001811906,0.0000249514],"domain_scores_gemma":[0.9998191,0.00004537146,0.00004579487,0.000008980691,0.000009068452,0.00007178701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7751987,0.0114789,0.003383038,0.0009204442,0.001054005,0.0001310506,0.0001436951,0.002242511,0.02566198,0.0002387053,0.001910951,0.177636],"study_design_scores_gemma":[0.408253,0.5503575,0.02539793,0.0001260131,0.001439205,0.0003896863,0.0000811437,0.003530924,0.0064288,0.0003426248,0.003613625,0.0000395631],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937252,0.004153325,0.0001679288,0.0001834166,0.00007555537,0.0002769114,0.0001897246,0.00005032334,0.001177612],"genre_scores_gemma":[0.9955814,0.00168366,0.0005071783,0.0002324687,0.00008195476,0.0002058408,0.0004381913,0.000008266991,0.001260878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002903323,"threshold_uncertainty_score":0.009712577,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.195411538090718,"score_gpt":0.513257776138573,"score_spread":0.317846238047855,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}